Dallas, TX -- (ReleaseWire) -- 01/23/2014 -- The Outlook for Pharmaceuticals in Latin America (http://www.reportsnreports.com/reports/53464-the-outlook-for-pharmaceuticals-in-latin-america.html) - Strong pharmaceutical market growth opportunities and regulatory developments are making Latin America more attractive
The region needs to increase drug access, despite intensifying cost-containment measures. Therefore, attractive opportunities for (bio) pharmaceutical producers exist in Latin America. Brazil has the largest pharmaceutical market. Strong economic performance will fuel pharmacy sales growth in the forecast period. Mexico is the second leading market. Recent regulatory developments will create further market opportunities in the country, particularly for generic producers in both the private and public sectors. In Argentina, the pharmaceutical industry is expected to perform well in the coming years, with strong growth in production, sales, exports and employment. Pharmaceutical companies, however, are encouraged to act in smaller Latin American markets to maximise and counterbalance their full regional sales potential.
Brazil and Mexico aim to become global leaders in the regulation of biologic and biosimilar medicines
In Brazil, ANVISA is expected to publish specific guidelines for the development of biosimilars of monoclonal antibodies in 2012; the agency published four guidelines for biosimilars in October 2011. Along with these guidelines, ANVISA created a technical chamber for biologics. The Ministry of Health is very keen to encourage the local production of biosimilars, whilst both local and foreign companies consider the biosimilar sector very attractive and are making slow but steady progress. In Mexico, a new decree that reformed and updated the Regulation of Health Supplies (RIS) in terms of biologic medicines was signed and published in the official bulletin (DOF) in October 2011. The new decree provides the legal requirements for any company interested in registering a biologic or biosimilar drug.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=53464.
THESE REPORTS ANALYSE THE ISSUES
The Outlook for Pharmaceuticals in Latin America is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.
Request Sample for this Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=53464.
Use these original and insightful reports to...
- Assess future market values with our unique and regularly reviewed independent 5-year market forecasts.
- Track the latest developments with the news service that is included for every country.
- Understand the critical issues and drivers which are shaping the market.
- Evaluate the environment for branded and generic operators and stay in touch with the fast growing biologic sector.
- Shape and support business plans and decisions with reliable business data.
- Benchmark key market performance with standardized data
The Outlook for Medical Devices in Latin America (http://www.reportsnreports.com/reports/53538-the-outlook-for-medical-devices-in-latin-america.html) - The eight Latin American medical markets covered by Espicom Business Intelligence represent a market of 497 million people with a GDP of US$5.4 trillion in 2013. After a recent period of remarkable growth, economic growth in the region is expected to be steady in 2013, except in Venezuela, affected by a weakening local currency. The region is seeing all markets re-evaluate their health provision. Levels of service in the buoyant private health sector are among the best to be found, but the challenge is to provide better levels of basic healthcare to the mass of the population. Opportunities for manufacturers of medical equipment and supplies do exist, but it is knowing where and how to develop them. Brazil is the largest medical market, followed by Mexico, Venezuela, Colombia and Argentina.
With the exception of Brazil and Mexico, the medical regulatory environment in the region is less stable than in developed markets. These young markets have not matured yet, therefore their regulatory systems are being consolidated. Brazil and Mexico, however, have more complex and mature regulatory systems. MERCOSUR members tend to follow the medical regulation established by Brazil and Argentina, and there is some degree of regulatory harmonisation among them. Andean members such as Colombia and Peru are also modelling Brazil’s medical regulation. Mexico operates closer to its North American allies, and follows the US FDA regulation.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=53538.
Trade in medical devices and equipment is key to the region’s development with all markets dependent on imports, with the exception of Brazil, which has a strong local domestic industry. Brazil, Argentina and Chile import more high specification medical technology products, whilst Peru, Mexico and Venezuela import more consumables. Regional medical exports are low, with the exception of Mexico, which represents nearly 90% of the region’s export capabilities. Continuing strong export growth in the country is almost entirely due to US manufacturers’ ‘maquiladora activities. Brazil’s exports are low compared to the size of its medical market, even though exports have more than doubled in the last eight years. The deficit in the balance of trade has increased in recent years, in spite of the weight of Mexico’s exports.
Request Sample for this Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=53538.
These reports provide highlights from the region.